After eight-straight monthly losses starting in April 2023, the shares of pharmaceutical concern Bristol-Meyers Squibb Co (NYSE:BMY) started to rebound in December, though were swiftly rejected by the 80-day moving average at the start of the year. Now, it looks like that bounce was indeed short-lived, as BMY is seeing even more pressure on the charts after its recent dip. According to Schaeffer's Senior Quantitative Analyst Rocky White, Bristol-Meyers stock is within one standard deviation of its 50-day an ...